Prosecution Insights
Last updated: May 29, 2026
Application No. 17/387,883

PSILOCIN DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERS

Non-Final OA §102§112
Filed
Jul 28, 2021
Priority
Feb 04, 2020 — provisional 62/969,934 +1 more
Examiner
MCDOWELL, BRIAN E
Art Unit
1624
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Mindset Pharma Inc.
OA Round
11 (Non-Final)
74%
Grant Probability
Favorable
11-12
OA Rounds
0m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 74% — above average
74%
Career Allowance Rate
825 granted / 1111 resolved
+14.3% vs TC avg
Strong +31% interview lift
Without
With
+30.6%
Interview Lift
resolved cases with interview
Typical timeline
2y 2m
Avg Prosecution
47 currently pending
Career history
1169
Total Applications
across all art units

Statute-Specific Performance

§101
0.3%
-39.7% vs TC avg
§103
23.5%
-16.5% vs TC avg
§102
19.1%
-20.9% vs TC avg
§112
51.1%
+11.1% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1111 resolved cases

Office Action

§102 §112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 9/15/2025 has been entered. DETAILED ACTION Status of Claims Claims 1-18, 20-26, 28-30, and 32-58 are pending. Claims 55-58 are new claims and drawn to the elected group and species. Claims 3,8,11,13, 20,22,24,29, 30, 32, 33, 38, 39, and 43-54 are withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected invention, there being no allowable generic or linking claim. An action on the merits of claims 1-2,4-7,9-10,12,14-18,21,23,25, 26, 28,34-37, 40-42, and 55-58 is contained herein. Previous Objections/Rejections Any rejections or objections stated of record in the office action mailed on 6/18/2025 that are not explicitly addressed herein below, are hereby withdrawn in light of applicant's arguments and/or amendments filed 9/15/2025. Information Disclosure Statement The examiner has considered the information disclosure statement filed most recently of record. Status of Rejections Double Patenting The rejection of claims 1-2,4-7,9-10,12,14-16,21,23,25, 28,34, 36, and 37 is maintained with respect to copending Application No. 18/982452. Applicant’s arguments, see Remarks, filed 9/15/2025 with respect to the rejection set forth in the Non-Final Office Action mailed 6/18/2025, have been fully considered and the rejection will be held in abeyance. New Rejections Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b). Claims 55-56 are provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-26 of copending Application No. 18/982452. Although the conflicting claims are not identical, they are not patentably distinct from each other because there is significant overlap between the two applications. The genus structure of the instant application may fully encompass the claimed subgenus and specific compounds in the copending application. For instance in the copending application, the claimed compounds specifically within the scope of variables Y, X, and A (other remaining variables the same) as shown below may anticipate the claimed subject matter: PNG media_image1.png 130 674 media_image1.png Greyscale This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(d): (d) REFERENCE IN DEPENDENT FORMS.—Subject to subsection (e), a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), fourth paragraph: Subject to the [fifth paragraph of 35 U.S.C. 112 (pre-AIA )], a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. Claim 35 is rejected under 35 U.S.C. 112(d) or pre-AIA 35 U.S.C. 112, 4th paragraph, as being of improper dependent form for failing to further limit the subject matter of the claim upon which it depends, or for failing to include all the limitations of the claim upon which it depends. Claim 35 does not further limit claim 34 since claim 34 already sets forth in the proviso that A must be selected from “C(O)N(Q’)2” or “C(O)Q’” when Y is X-A. Applicant may cancel the claim(s), amend the claim(s) to place the claim(s) in proper dependent form, rewrite the claim(s) in independent form, or present a sufficient showing that the dependent claim(s) complies with the statutory requirements. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale or otherwise available to the public before the effective filing date of the claimed invention. Claims 1, 2, 4-7, 9, 10, 12, 14, and 55-56 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by CH 414639 (abstract). CH 414639 teaches the below compound and compositions thereof (see compound in CaCl2 solution in abstract): PNG media_image2.png 722 800 media_image2.png Greyscale wherein the above compound have the limitations; R1-R6, R9-R11 are hydrogen, Y is X-A; X is S; and A is –CH2aryl, and R7,R8 are hydrogen in an amount . Thus the claims are anticipated. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), first paragraph: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claims 1-2,4-7,9-10,12,14-18,21,23,25, 28,34-37, and 55-58 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for pre-AIA the inventor(s), at the time the application was filed, had possession of the claimed invention. The newly presented proviso limitation set forth in claims 1 and 34 constitutes new matter with respect to: PNG media_image3.png 38 440 media_image3.png Greyscale This particular proviso was not found in the specification as originally filed nor the claims. Thus, the examiner must look to the working examples for support where no specific examples were disclosed. Furthermore, there appears to be no blazemarks set forth in the disclosure as well where one would arrive at the expanded definition for variable Q’ for this proviso as a whole. Thus, the proviso presented as a whole is not supported by the disclosure or any of the working examples therein. The examiner notes that this is essentially a new subgenus presented by Applicant within the claim to obviate the art of record. However, PNG media_image4.png 200 400 media_image4.png Greyscale Thus, the rejection is appropriately applied. An amendment to the claims or the addition of a new claim must be supported by the description of the invention in the application as filed. In re Wright, 866 F.2d 422, 9 USPQ2d 1649 (Fed. Cir. 1989). Conclusion Claims 1-2,4-7,9-10,12,14-18,21,23,25, 28,34-37, and 55-58 are rejected. Claims 40-42 are allowable. Claim 26 is objected to as being dependent upon a rejected or objected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. Any inquiry concerning this communication or earlier communications from the examiner should be directed to BRIAN E MCDOWELL whose telephone number is (571)270-5755. The examiner can normally be reached on 8:30-6 MF. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jeffrey Murray can be reached at 571-272-9023. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /BRIAN E MCDOWELL/ Primary Examiner, Art Unit 1624
Read full office action

Prosecution Timeline

Show 34 earlier events
Sep 18, 2025
Response after Non-Final Action
Nov 28, 2025
Non-Final Rejection mailed — §102, §112
Mar 18, 2026
Applicant Interview (Telephonic)
Mar 18, 2026
Examiner Interview Summary
Mar 26, 2026
Response Filed
Mar 26, 2026
Response after Non-Final Action
May 19, 2026
Applicant Interview (Telephonic)
May 19, 2026
Examiner Interview Summary

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12636371
Chemically Coupled Transporter for Low-Hydrophobicity Bioactive Drugs into the Central Nervous System
2y 2m to grant Granted May 26, 2026
Patent 12617782
PYRIDAZINONES AS PARP7 INHIBITORS
2y 11m to grant Granted May 05, 2026
Patent 12617774
SUBSTITUTED INDOLE COMPOUNDS AND METHODS OF USE THEREOF
11m to grant Granted May 05, 2026
Patent 12612381
CRYSTALLINE FORMS OF N-(4-(4-(CYCLOPROPYLMETHYL)PIPERAZINE-1-CARBONYL)PHENYL)QUINOLINE-8-SULFONAMIDE
4y 3m to grant Granted Apr 28, 2026
Patent 12606556
TYK-2 INHIBITOR
3y 8m to grant Granted Apr 21, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

11-12
Expected OA Rounds
74%
Grant Probability
99%
With Interview (+30.6%)
2y 2m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 1111 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month